CENCORA, INC.
At today's price, CENCORA, INC. (COR) is priced for -1.4% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
- Cencora is a pharmaceutical distribution giant, the renamed AmerisourceBergen, with Human Health (US drug distribution) making up about 89% of its value and the OneOncology specialty business now a growth engine. This is a mature, razor-thin-margin, high-volume business where scale is the moat. - At $271.90 no valuation family reaches the price. It is rich on assets, earnings power, peers, and even forward growth, so the price is a bet beyond what any standard frame supports. Inverting it impl
Is COR overvalued? See what's priced in →
1,385 institutional managers reported holding COR in 13F filings for the quarter ended 2026-03-31. Together they hold about 78% of the company; the top 10 hold 37%. 112 opened new positions that quarter. Held by BlackRock, State Street, T. Rowe Price, among others. On the short side, 6.2M shares were sold short as of the 2026-06-15 count, about 3% of shares outstanding (4.7 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
COR has cut its share count 5.6% over the past five years, spending $3.64B on repurchases. It pays a dividend, and has paid one every year in our records (18 and counting), raised 17 years straight; the current rate is $2.20 a share annually. Cash returned over the past three years: $1.20B in dividends and $2.22B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at COR over the trailing three years: 2024: 1 buy totaling $109k; 2026: 3 buys totaling $2.31M. 18 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
COR's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-03 | +1.2% | -3.3% |
| 2023-11-22 | -2.8% | +8.9% |
| 2024-02-01 | +7.4% | +2.2% |
| 2024-05-02 | -6.0% | -1.0% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
COR's latest 8-K filings: 2026-06-15 (items 5.02, 7.01, 9.01); 2026-05-29 (items 5.02, 7.01, 9.01); 2026-05-06 (items 2.02, 7.01, 9.01); 2026-03-23 (items 7.01, 9.01); 2026-03-17 (items 5.02, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.